scholarly journals Autologous platelet-rich plasma combined with hyaluronic acid is a new method of minimally invasive treatment of stress urinary incontinence in women

2018 ◽  
pp. 16-20
Author(s):  
I. A. Apolikhina ◽  
A. V. Sokolova ◽  
A. S. Saidova ◽  
E. A. Gorbunova
Keyword(s):  
Urinary Incontinence ◽  
Hyaluronic Acid ◽  
Stress Urinary Incontinence ◽  
Platelet Rich Plasma ◽  
Physiological Mechanism ◽  
Common Disease ◽  
Invasive Treatment ◽  
Autologous Plasma ◽  
Autologous Platelet Rich Plasma ◽  
Autologous Platelet

Stress urinary incontinence (SUI) is a common disease. It is 2 times more common among women than in men. The causes of SUI are the insufficiency of the closing function of the sphincter of the bladder and/or hypermobility of the urethra. For this reason, methods aimed at improving the closing function of the urethra, i.e., the use of volume-forming agents are justified for the treatment of this disease. Side effects and time-limited relief of symptoms of urinary incontinence after the application of volumeforming agents, or at the other hand complications after surgery lead to the search for alternative treatments that can restore the natural physiological mechanism of urinary retention. This study demonstrates that administration of platelet-rich autologous plasma in combination with hyaluronic acid in the periurethral region is a safe and effective method of treatment of SUI in women.

scholarly journals A pilot study: effectiveness of local injection of autologous platelet-rich plasma in treating women with stress urinary incontinence

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Cheng-Yu Long ◽  
Kun-Ling Lin ◽  
Chin-Ru Shen ◽  
Chin-Ru Ker ◽  
Yi-Yin Liu ◽  
...  
Keyword(s):  
Urinary Incontinence ◽  
Pilot Study ◽  
Stress Urinary Incontinence ◽  
Sexual Function ◽  
Treatment Effect ◽  
Platelet Rich Plasma ◽  
Post Treatment ◽  
Local Injection ◽  
Autologous Platelet Rich Plasma ◽  
Autologous Platelet

AbstractThe study aims to evaluate the effectiveness of local injection of autologous platelet rich plasma (A-PRP) as a treatment for women suffering from stress urinary incontinence (SUI). In a prospective intervention study, twenty consecutive women suffering from SUI were treated with A-PRP injection at anterior vaginal wall where mid-urethra locates. Self-reported questionnaires were used to measure pre-treatment, 1 month and 6 months post-treatment symptom severity. Secondary outcomes of sexual function and treatment effect sorted by age were analyzed with valid statistical methods. A-PRP is effective in relieving SUI symptoms at both 1 month and 6 months post-treatment without significant adverse reactions reported. It seems to have a trend that treatment success rate with cured and improved symptoms was slightly higher in the younger group, although it did not reach statistical significance (P = 0.07). No significant changes in sexual function before and after the treatment were reported by the patients. This pilot study is the first to report A-PRP treatment effect for SUI in women. The result suggested that A-PRP is a considerable treatment option for mild to moderate SUI cases. It also opens up further research opportunities for A-PRP’s clinical applications.

The Effectiveness of Autologous Platelet-Rich Plasma for Osteoarthritis of the Hip: A Retrospective Analysis

Pain Medicine ◽  
2019 ◽  
Vol 20 (8) ◽  
pp. 1611-1618 ◽  
Author(s):  
Jaspal Ricky Singh ◽  
Paul Haffey ◽  
Ali Valimahomed ◽  
Alfred C Gellhorn
Keyword(s):  
Daily Living ◽  
Platelet Rich Plasma ◽  
Hip Osteoarthritis ◽  
Functional Improvement ◽  
Inclusion Criteria ◽  
Invasive Treatment ◽  
Tissue Healing ◽  
Provide Pain Relief ◽  
Autologous Platelet Rich Plasma ◽  
Autologous Platelet

AbstractBackgroundPlatelet-rich plasma (PRP) is a minimally invasive treatment option to reduce pain and promote tissue healing. At the time this study was performed, there was limited published literature analyzing outcomes for patients treated with PRP for hip osteoarthritis.MethodsThirty-six patients aged 49–85 (66.0 ± 12.1) years with chronic hip pain who met inclusion criteria underwent image-guided intra-articular hip PRP injection. Outcomes were measured at baseline, two weeks, three months, and up to six months using the visual analog scale (VAS) for pain and the Hip Disability and Osteoarthritis Outcome Score (HOOS). The proportion of responders, as defined by a ≥50% reduction in VAS pain score, was assessed at three and six months.ResultsAt two weeks, there was a significant improvement (P < 0.05) of function in two HOOS subscales: Symptoms and Activities of Daily Living. There was a significant improvement in all HOOS categories at six months. A significant improvement in VAS was observed at six months (baseline VAS = 6.9 ± 0.7 &→ 4.3 ± 1.8, 95% confidence interval = 2.0 to 3.2, P < 0.05). Sixty-seven percent (24/36) of the patients reported a ≥50% improvement in pain at three months; 58% (21/36) reported a ≥50% improvement in pain at six months. Stratification by Kellgren-Lawrence grades revealed that 86% and 82% of the KL grades 1 and 2 were responders at six months, respectively.ConclusionsIn patients with mild/moderate hip osteoarthritis, PRP may provide pain relief and functional improvement for up to six months.

Complex treatment of uveitis with macular edema associated with systemic diseases using autologous platelet-rich plasma

2021 ◽  
pp. 148-152
Author(s):  
N.S. Arbenyeva ◽  
◽  
V.I. Bratko ◽  
A.N. Trunov ◽  
V.V. Chernykh ◽  
...  
Keyword(s):  
Macular Edema ◽  
Comparison Group ◽  
Platelet Rich Plasma ◽  
Ophthalmological Examination ◽  
Systemic Diseases ◽  
Complex Treatment ◽  
Autologous Plasma ◽  
Autologous Platelet Rich Plasma ◽  
Anti Inflammatory ◽  
Autologous Platelet

In patients with uveitis associated with systemic diseases, a common cause of low vision is macular edema, which develops at any localization of the inflammatory process in 38–84% of cases. Autologous platelet-rich plasma is widely used in various branches of medicine, however, in the treatment of uveitis accompanied by macular edema, the clinical efficacy of its use has not been sufficiently studied. Purpose. To conduct a clinical and laboratory assessment of the effectiveness of complex treatment of uveitis with macular edema associated with systemic diseases using autologous platelet-rich plasma. Material and methods. The study included 120 people (120 eyes) from 18 to 50 years old with uveitis and macular edema associated with systemic diseases: 51 men, 69 women. Patients were divided into 2 groups: the main group consisted of patients who received anti-inflammatory treatment and administration of autologous plasma platelet-rich; comparison group – patients who received anti-inflammatory treatment. All patients underwent a comprehensive ophthalmological examination. Results. It has been established that the administration of autologous platelet-rich plasma against the background of anti-inflammatory treatment in patients with uveitis associated with systemic diseases accompanied by macular edema improves the maximally corrected visual acuity, a statistically significant decrease in the thickness of the retina in the fovea and an increase in the light sensitivity of the retina, relative to the data obtained in the comparison group. Conclusion. The use of autologous platelet-rich plasma in combination with anti-inflammatory treatment leads to a decrease in the incidence of recurrence of uveitis associated with systemic diseases, helps to reduce macular edema and improve functional parameters. Key words: uveitis, macular edema, anti-inflammatory treatment, autologous platelet-rich plasma.

Sign in / Sign up

Export Citation Format

Share Document